PMID- 36926333
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230327
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Unique profile on the progress free survival and overall survival in patients 
      with advanced non-small cell lung cancer in the Qujing area, Southwest China.
PG  - 1012166
LID - 10.3389/fimmu.2023.1012166 [doi]
LID - 1012166
AB  - BACKGROUND: China's southwestern region, Qujing, harbors a high incidence of 
      non-small cell lung cancer (NSCLC) and related mortality. This study was designed 
      to reveal the impact of an immune-related prognostic signature (IRPS) on advanced 
      NSCLC in the Qujing. METHODS: Tissue specimens from an independent cohort of 37 
      patients with advanced NSCLC were retrospectively evaluated to determine the 
      relationship between the IRPS estimated by next-generation sequencing (NGS) and 
      clinical outcome. To compare the IRPS in tissue and the clinical outcomes between 
      Qujing and non-Qujing populations, we analyzed datasets of 23 patients with 
      advanced NSCLC from The Cancer Genome Atlas (TCGA) database. In addition, an 
      independent cohort (n=111) of blood specimens was retrospectively analyzed to 
      determine the relationship between the IRPS and clinical outcome. Finally, we 
      evaluated the utility of the blood IRPS in classifying 24 patients with advanced 
      NSCLC who might benefit from immunotherapy. RESULTS: In cohort 1, the Qujing 
      population with tTMB-H (>/= 10 mutations/Mb) or KRAS mutations had shorter 
      progression-free survival (PFS) (hazard ratio [HR] 0.37, 0.14 to 0.97, P = 0.04; 
      HR 0.23, 0.08 to 0.66, P < 0.01) and overall survival (OS) (HR 0.05, 0.01 to 
      0.35, P < 0.01; HR 0.22, 0.07 to 0.66, P < 0.01). In cohort 2 of the Qujing 
      population, bTMB-H (>/= 6 mutations per Mb) and KRAS mutations were related to PFS 
      (HR 0.59, 0.36 to 0.99, P = 0.04; HR 0.50, 0.26 to 0.98, P = 0.04) and OS (HR 
      0.58, 0.35 to 0.96, P = 0.03; HR 0.48, 0.25 to 0.93, P = 0.03). Notably, the 
      Qujing population with bTMB-H had superior PFS (HR 0.32, 0.09 to 1.09, P = 0.01), 
      OS (HR 0.33, 0.10 to 1.13, P < 0.01) and objective response rates (ORRs) (83.3% 
      vs. 14.3% vs. 20.0%, P <0.01) to immunotherapy than other populations. 
      CONCLUSIONS: These findings show that tTMB, bTMB and KRAS mutations appear to be 
      independent validated IRPSs that predict the clinical outcomes of Qujing 
      populations with advanced NSCLC and that bTMB may be used as a reliable IRPS to 
      predict the clinical benefit from anti-PD-1 therapies among populations from 
      Qujing with advanced NSCLC.
CI  - Copyright (c) 2023 Ma, Shi, Zhao, Liu, Cai, Li, Chen, Lei, Ye, Fu, Zhao, Zhou and 
      Huang.
FAU - Ma, Yuhui
AU  - Ma Y
AD  - Department of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, China.
FAU - Shi, Hutao
AU  - Shi H
AD  - Department of Imaging at Kunming Tongren Hospital, Kunming, China.
FAU - Zhao, Guangqiang
AU  - Zhao G
AD  - Department of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, China.
FAU - Liu, Xin
AU  - Liu X
AD  - Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical 
      University, Yunnan Cancer Center, Kunming, China.
FAU - Cai, Jingjing
AU  - Cai J
AD  - Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical 
      University, Yunnan Cancer Center, Kunming, China.
FAU - Li, Guangjian
AU  - Li G
AD  - Department of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, China.
FAU - Chen, Wanlin
AU  - Chen W
AD  - Department of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, China.
FAU - Lei, Yujie
AU  - Lei Y
AD  - Department of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, China.
FAU - Ye, Lianhua
AU  - Ye L
AD  - Department of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, China.
FAU - Fu, Chaojiang
AU  - Fu C
AD  - Emergency Department (Outpatient Chemotherapy Center) at Yunnan Cancer Hospital, 
      Kunming, China.
FAU - Zhao, Li
AU  - Zhao L
AD  - Department of Anesthesiology at Yunnan Cancer Hospital, Kunming, China.
FAU - Zhou, Yongchun
AU  - Zhou Y
AD  - Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical 
      University, Yunnan Cancer Center, Kunming, China.
FAU - Huang, Yunchao
AU  - Huang Y
AD  - Department of Thoracic Surgery I, The Yunnan Cancer Hospital, Kunming, China.
AD  - Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical 
      University, Yunnan Cancer Center, Kunming, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230228
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Lung Neoplasms/drug therapy
MH  - Retrospective Studies
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Biomarkers, Tumor/genetics
PMC - PMC10011462
OTO - NOTNLM
OT  - NSCLC
OT  - Qujing
OT  - immune signature
OT  - immunotherapy
OT  - predictive biomarker
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/18 06:00
MHDA- 2023/03/21 06:00
PMCR- 2023/01/01
CRDT- 2023/03/17 02:48
PHST- 2022/08/05 00:00 [received]
PHST- 2023/02/10 00:00 [accepted]
PHST- 2023/03/17 02:48 [entrez]
PHST- 2023/03/18 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1012166 [doi]
PST - epublish
SO  - Front Immunol. 2023 Feb 28;14:1012166. doi: 10.3389/fimmu.2023.1012166. 
      eCollection 2023.